IDEAS home Printed from https://ideas.repec.org/e/c/pje47.html
   My authors  Follow this author

Anupam B. Jena

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Meltzer, David O. & Jena, Anupam B., 2010. "The economics of intense exercise," Journal of Health Economics, Elsevier, vol. 29(3), pages 347-352, May.

    Mentioned in:

    1. Links 1/03/2011
      by Liam Delaney in Geary Behaviour Centre on 2011-03-01 21:54:00

Working papers

  1. Michael D. Frakes & Jonathan Gruber & Anupam Jena, 2019. "Is Great Information Good Enough? Evidence from Physicians as Patients," NBER Working Papers 26038, National Bureau of Economic Research, Inc.

    Cited by:

    1. van der Klaauw, Bas & Artmann, Elisabeth & Oosterbeek, Hessel, 2019. "Do doctors improve the health care of their parents? Evidence from admission lotteries," CEPR Discussion Papers 14061, C.E.P.R. Discussion Papers.

  2. Michael Frakes & Anupam B. Jena, 2014. "Does Medical Malpractice Law Improve Health Care Quality?," NBER Working Papers 19841, National Bureau of Economic Research, Inc.

    Cited by:

    1. Matter, Ulrich & Stutzer, Alois, 2015. "Politico-economic determinants of tort reforms in medical malpractice," Working papers 2015/02, Faculty of Business and Economics - University of Basel.
    2. Patricia H. Born & J. Bradley Karl, 2016. "The Effect of Tort Reform on Medical Malpractice Insurance Market Trends," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 13(4), pages 718-755, December.
    3. Bertoli, Paola & Grembi, Veronica, 2019. "Malpractice risk and medical treatment selection," Journal of Public Economics, Elsevier, vol. 174(C), pages 22-35.
    4. Matter, Ulrich & Stutzer, Alois, 2016. "The role of party politics in medical malpractice tort reforms," European Journal of Political Economy, Elsevier, vol. 42(C), pages 17-35.
    5. Galasso, Alberto & Luo, Hong, 2018. "How does product liability risk affect innovation? Evidence from medical implants," CEPR Discussion Papers 13036, C.E.P.R. Discussion Papers.
    6. Alberto Galasso & Hong Luo, 2018. "When does Product Liability Risk Chill Innovation? Evidence from Medical Implants," NBER Working Papers 25068, National Bureau of Economic Research, Inc.
    7. Panthöfer, Sebastian, 2016. "Tort Reform and the Length of Physician Office Visits," UC3M Working papers. Economics 23861, Universidad Carlos III de Madrid. Departamento de Economía.
    8. Michael D. Frakes & Jonathan Gruber, 2018. "Defensive Medicine: Evidence from Military Immunity," NBER Working Papers 24846, National Bureau of Economic Research, Inc.

  3. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," NBER Working Papers 16990, National Bureau of Economic Research, Inc.

    Cited by:

    1. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
    2. Cox, James C. & Sadiraj, Vjollca & Schnier, Kurt E. & Sweeney, John F., 2016. "Higher quality and lower cost from improving hospital discharge decision making," Journal of Economic Behavior & Organization, Elsevier, vol. 131(PB), pages 1-16.
    3. Liran Einav & Amy Finkelstein & Heidi Williams, 2016. "Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments," American Economic Journal: Economic Policy, American Economic Association, vol. 8(1), pages 52-79, February.
    4. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    5. David H. Howard & Yu-Chu Shen, 2011. "Comparative Effectiveness Research, COURAGE, and Technological Abandonment," NBER Working Papers 17371, National Bureau of Economic Research, Inc.
    6. Amitabh Chandra & Jonathan Skinner, 2012. "Technology Growth and Expenditure Growth in Health Care," Journal of Economic Literature, American Economic Association, vol. 50(3), pages 645-680, September.
    7. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
    8. Wu, Bingxiao & David, Guy, 2022. "Information, relative skill, and technology abandonment," Journal of Health Economics, Elsevier, vol. 83(C).
    9. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.

  4. Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.

    Cited by:

    1. Frank R. Lichtenberg, 2014. "Has Medical Innovation Reduced Cancer Mortality?," CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
    2. Kyle, Margaret & Dubois, Pierre, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality," CEPR Discussion Papers 11487, C.E.P.R. Discussion Papers.
    3. Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena, 2017. "Defining Value: The Need for a Longer, Broader View," PharmacoEconomics, Springer, vol. 35(7), pages 669-672, July.
    4. Christoph M Rheinberger & Daniel Herrera-Araujo & James K. Hammitt, 2016. "The value of disease prevention vs treatment," Post-Print halshs-01626801, HAL.
    5. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
    6. Kyle R. Myers, 2022. "Some Tradeoffs of Competition in Grant Contests," Papers 2207.02379, arXiv.org, revised Mar 2024.
    7. Rebecca Mary Myerson & Reginald Tucker-Seeley & Dana Goldman & Darius N. Lakdawalla, 2019. "Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?," NBER Working Papers 26292, National Bureau of Economic Research, Inc.
    8. Adam Leive & Thomas Stratmann, 2015. "Do national cancer screening guidelines reduce mortality?," Journal of Population Economics, Springer;European Society for Population Economics, vol. 28(4), pages 1075-1095, October.
    9. Laura Grigolon & Laura Lasio, 2023. "Biased Beliefs and Stigma as Barriers to Treatment and Innovation Adoption," CRC TR 224 Discussion Paper Series crctr224_2023_277v2, University of Bonn and University of Mannheim, Germany.
    10. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    11. Hintermann, Beat & Minke, Matthias, 2018. "The value of extending life at its end: Health care allocation in the presence of learning spillovers," Working papers 2018/15, Faculty of Business and Economics - University of Basel.
    12. David E. Bloom & Simiao Chen & Michael Kuhn & Mark E. McGovern & Les Oxley & Klaus Prettner, 2017. "The Economic Burden of Chronic Diseases: Estimates and Projections for China, Japan, and South Korea," NBER Working Papers 23601, National Bureau of Economic Research, Inc.
    13. Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
    14. Hammitt, James K. & Herrera-Araujo, Daniel & Rheinberger, Christoph, 2016. "The Value of Cancer Prevention vs Treatment," TSE Working Papers 16-628, Toulouse School of Economics (TSE).
    15. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
    16. Amitabh Chandra, 2011. "Comment on "The Value of Progress against Cancer in the Elderly"," NBER Chapters, in: Investigations in the Economics of Aging, pages 233-236, National Bureau of Economic Research, Inc.
    17. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
    18. Dubois, Pierre & Kyle, Margaret, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality Rates," TSE Working Papers 16-688, Toulouse School of Economics (TSE).
    19. Engy Ziedan & Kosali I. Simon & Coady Wing, 2022. "Mortality Effects of Healthcare Supply Shocks: Evidence Using Linked Deaths and Electronic Health Records," NBER Working Papers 30553, National Bureau of Economic Research, Inc.

  5. Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.

    Cited by:

    1. Elamin Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    2. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    3. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
    4. Anirban Basu & Tomas J. Philipson, 2010. "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," NBER Working Papers 15633, National Bureau of Economic Research, Inc.
    5. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
    6. Ben van Hout & Jolian McHardy & Aki Tsuchiya, 2015. "Patent Purchase as a Policy for Pharmaceuticals," Working Papers 2015007, The University of Sheffield, Department of Economics.
    7. Yupeng Liu & Yutao Yang & Yue Liu & Gwo-Hshiung Tzeng, 2019. "Improving Sustainable Mobile Health Care Promotion: A Novel Hybrid MCDM Method," Sustainability, MDPI, vol. 11(3), pages 1-29, January.
    8. Basu, Anirban, 2011. "Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care," Journal of Health Economics, Elsevier, vol. 30(3), pages 549-559, May.
    9. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    10. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    11. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
    12. Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2022. "The price of cost-effectiveness thresholds," NIPE Working Papers 5/2022, NIPE - Universidade do Minho.
    13. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," NBER Working Papers 16990, National Bureau of Economic Research, Inc.
    14. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
    15. Carlos Campillo-Artero & Jaume Puig-Junoy & José Luis Segú-Tolsa & Marta Trapero-Bertran, 2020. "Price Models for Multi-indication Drugs: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 47-56, February.
    16. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
    17. William S. Comanor & Stuart O. Schweitzer & Jon M. Riddle & Frederic Schoenberg, 2018. "Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matter?," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 52(4), pages 589-602, June.
    18. Besanko, David & Dranove, David & Garthwaite, Craig, 2020. "Insurance access and demand response: Pricing and welfare implications," Journal of Health Economics, Elsevier, vol. 73(C).
    19. Maximilian Hatz & Katharina Schremser & Wolf Rogowski, 2014. "Is Individualized Medicine More Cost-Effective? A Systematic Review," PharmacoEconomics, Springer, vol. 32(5), pages 443-455, May.
    20. Rosella Levaggi & Paolo Pertile, 2016. "Pricing policies when patients are heterogeneous: a welfare analysis," Working Papers 17/2016, University of Verona, Department of Economics.
    21. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    22. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
    23. Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin, 2010. "Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1109-1116, October.

  6. Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun, 2008. "The Value of Life in General Equilibrium," NBER Working Papers 14157, National Bureau of Economic Research, Inc.

    Cited by:

    1. Andr'es Riquelme & Marcela Parada, 2016. "The Value of A Statistical Life in Absence of Panel Data: What can we do?," Papers 1603.00568, arXiv.org.
    2. Moshe Hazan, 2009. "Longevity and Lifetime Labor Supply: Evidence and Implications," Econometrica, Econometric Society, vol. 77(6), pages 1829-1863, November.
    3. Eszter Czibor & David Jimenez-Gomez & John A. List, 2019. "The Dozen Things Experimental Economists Should Do (More of)," NBER Working Papers 25451, National Bureau of Economic Research, Inc.
    4. Thomas J. Kniesner & W. Kip Viscusi & Christopher Woock & James P. Ziliak, 2010. "The Value of a Statistical Life: Evidence from Panel Data," Center for Policy Research Working Papers 122, Center for Policy Research, Maxwell School, Syracuse University.
    5. Hoyt Bleakley, 2009. "Comment on "When Does Improving Health Raise GDP?"," NBER Chapters, in: NBER Macroeconomics Annual 2008, Volume 23, pages 205-220, National Bureau of Economic Research, Inc.
    6. Mary F. Evans & V. Kerry Smith, 2009. "Measuring How Risk Tradeoffs Adjust With Income," NBER Working Papers 15372, National Bureau of Economic Research, Inc.

  7. Tomas Philipson & Stephane Mechoulan & Anupam Jena, 2006. "Health Care, Technological Change, and Altruistic Consumption Externalities," NBER Working Papers 11930, National Bureau of Economic Research, Inc.

    Cited by:

    1. Adrian Towse & Priya Sharma, 2011. "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 331-350.
    2. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
    3. Stéphane Mechoulan, 2006. "Risky Sexual Behavior, Testing and New HIV Treatments," Working Papers tecipa-239, University of Toronto, Department of Economics.

  8. Tomas J. Philipson & Anupam B. Jena, 2006. "Surplus Appropriation from R&D and Health Care Technology Assessment Procedures," NBER Working Papers 12016, National Bureau of Economic Research, Inc.

    Cited by:

    1. Pedro Pita Barros & Xavier Martínez-Giralt, 2009. "Technological adoption in health care," Working Papers 413, Barcelona School of Economics.
    2. Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
    3. Tomas Philipson & Stephane Mechoulan & Anupam Jena, 2006. "Health Care, Technological Change, and Altruistic Consumption Externalities," NBER Working Papers 11930, National Bureau of Economic Research, Inc.
    4. Lakdawalla, Darius & Sood, Neeraj, 2009. "Innovation and the welfare effects of public drug insurance," Journal of Public Economics, Elsevier, vol. 93(3-4), pages 541-548, April.
    5. Tomas J. Philipson & Anupam B. Jena, 2005. "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," NBER Working Papers 11810, National Bureau of Economic Research, Inc.
    6. Barros Pedro Pita & Martinez-Giralt Xavier, 2015. "Technological Adoption in Health Care – The Role of Payment Systems," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 15(2), pages 709-745, April.
    7. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 11, Edward Elgar Publishing.
    8. Fimpel, Julia & Stolpe, Michael, 2006. "The welfare costs of HIV/AIDS in Eastern Europe: An empirical assessment using the economic value-of-life approach," Kiel Working Papers 1297, Kiel Institute for the World Economy (IfW Kiel).
    9. Lundin Douglas & Ramsberg Joakim, 2008. "Dynamic Cost-Effectiveness: A More Efficient Reimbursement Criterion," Forum for Health Economics & Policy, De Gruyter, vol. 11(2), pages 1-17, November.

  9. Tomas J. Philipson & Anupam B. Jena, 2005. "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," NBER Working Papers 11810, National Bureau of Economic Research, Inc.

    Cited by:

    1. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    2. Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena, 2017. "Defining Value: The Need for a Longer, Broader View," PharmacoEconomics, Springer, vol. 35(7), pages 669-672, July.
    3. McKellar Michael R. & Frank Matthew & Huskamp Haiden & Chernew Michael E., 2012. "The Value of Patent Expiration," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-13, November.
    4. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
    5. Lakdawalla, Darius N. & Seabury, Seth A., 2012. "The welfare effects of medical malpractice liability," International Review of Law and Economics, Elsevier, vol. 32(4), pages 356-369.
    6. Alan M. Garber & Charles I. Jones & Paul M. Romer, 2006. "Insurance and Incentives for Medical Innovation," NBER Working Papers 12080, National Bureau of Economic Research, Inc.
    7. Lichtenberg Frank R., 2010. "Pharmaceutical Price Discrimination and Social Welfare," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-32, July.
    8. Thornton Snider Julia & Romley John A. & Vogt William B. & Philipson Tomas J., 2012. "The Option Value of Innovation," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-19, April.
    9. Victoria Baranov & Daniel Bennett & Hans-Peter Kohler, 2015. "The Indirect Impact of Antiretroviral Therapy: Mortality Risk, Mental Health, and HIV-Negative Labor Supply," Department of Economics - Working Papers Series 2002, The University of Melbourne.
    10. Tomas Philipson & Stephane Mechoulan & Anupam Jena, 2006. "Health Care, Technological Change, and Altruistic Consumption Externalities," NBER Working Papers 11930, National Bureau of Economic Research, Inc.
    11. Thornton Snider Julia & Seabury Seth & Tebeka Mahlet Gizaw & Wu Yanyu & Batt Katharine, 2018. "The Option Value of Innovative Treatments for Metastatic Melanoma," Forum for Health Economics & Policy, De Gruyter, vol. 21(1), pages 1-10, June.
    12. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    13. Amitabh Chandra & Jonathan Skinner, 2012. "Technology Growth and Expenditure Growth in Health Care," Journal of Economic Literature, American Economic Association, vol. 50(3), pages 645-680, September.
    14. Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010. "Terminal Care and The Value of Life Near Its End," NBER Working Papers 15649, National Bureau of Economic Research, Inc.
    15. Sun Eric & Jena Anupam B & Lakdawalla Darius & Reyes Carolina & Philipson Tomas J & Goldman Dana, 2010. "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000," Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-22, February.
    16. Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B., 2012. "A Reexamination of the Costs of Medical R&D Regulation," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-28, October.
    17. Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
    18. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner B. F. Brouwer, 2021. "The value of health—Empirical issues when estimating the monetary value of a quality‐adjusted life year based on well‐being data," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1849-1870, August.
    19. Julia Fimpel & Michael Stolpe, 2010. "The welfare costs of HIV/AIDS in Eastern Europe: an empirical assessment using the economic value-of-life approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 305-322, June.
    20. Sergi Alonso & Khátia Munguambe & Elisa Sicuri, 2017. "Market for Artemether‐Lumefantrine to treat childhood malaria in a district of southern Mozambique," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 345-360, December.
    21. Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497-518.
    22. Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
    23. Adrian Towse, 2007. "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 653-665, July.
    24. Darius Lakdawalla & Anup Malani & Julian Reif, 2015. "The Insurance Value of Medical Innovation," NBER Working Papers 21015, National Bureau of Economic Research, Inc.
    25. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner Brouwer, 2020. "The Value of Health - Empirical Issues when Estimating the Monetary Value of a QALY Based on Well-Being," SOEPpapers on Multidisciplinary Panel Data Research 1101, DIW Berlin, The German Socio-Economic Panel (SOEP).
    26. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
    27. Fimpel, Julia & Stolpe, Michael, 2006. "The welfare costs of HIV/AIDS in Eastern Europe: An empirical assessment using the economic value-of-life approach," Kiel Working Papers 1297, Kiel Institute for the World Economy (IfW Kiel).
    28. Tomas Philipson & Anupam B. Jena & Eric Sun, 2007. "The institute of medicine report on the FDA: where is the science?," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 219-221, March.
    29. Goldman Dana P. & Gupta Charu & Vasudeva Eshan & Trakas Kostas & Riley Ralph & Lakdawalla Darius & Agus David & Sood Neeraj & Jena Anupam B. & Philipson Tomas J., 2013. "The Value of Diagnostic Testing in Personalized Medicine," Forum for Health Economics & Policy, De Gruyter, vol. 16(2), pages 87-99, September.

Articles

  1. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," Journal of Economic Perspectives, American Economic Association, vol. 25(2), pages 27-46, Spring.
    See citations under working paper version above.
  2. Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011. "The impact of comparative effectiveness research on health and health care spending," Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.

    Cited by:

    1. Kristopher J. Hult, 2017. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments," NBER Working Papers 23900, National Bureau of Economic Research, Inc.
    2. Basu Anirban, 2013. "Personalized Medicine in the Context of Comparative Effectiveness Research," Forum for Health Economics & Policy, De Gruyter, vol. 16(2), pages 73-86, June.
    3. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
    4. Jena, Anupam B. & Philipson, Tomas J., 2013. "Endogenous cost-effectiveness analysis and health care technology adoption," Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
    5. Anirban Basu, 2012. "Estimating Person-Centered Treatment (PeT) Effects Using Instrumental Variables," NBER Working Papers 18056, National Bureau of Economic Research, Inc.
    6. Basu, Anirban, 2011. "Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care," Journal of Health Economics, Elsevier, vol. 30(3), pages 549-559, May.
    7. Michael R. Eber & Cass R. Sunstein & James K. Hammitt & Jennifer M. Yeh, 2021. "The modest effects of fact boxes on cancer screening," Journal of Risk and Uncertainty, Springer, vol. 62(1), pages 29-54, February.
    8. H. Evans & A. Basu, 2011. "Exploring comparative effect heterogeneity with instrumental variables: prehospital intubation and mortality," Health, Econometrics and Data Group (HEDG) Working Papers 11/26, HEDG, c/o Department of Economics, University of York.
    9. Mousnad, Mohamed Awad & Shafie, Asrul Akmal & Ibrahim, Mohamed Izham, 2014. "Systematic review of factors affecting pharmaceutical expenditures," Health Policy, Elsevier, vol. 116(2), pages 137-146.
    10. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," NBER Working Papers 16990, National Bureau of Economic Research, Inc.
    11. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
    12. Basu, Anirban, 2015. "Welfare implications of learning through solicitation versus diversification in health care," Journal of Health Economics, Elsevier, vol. 42(C), pages 165-173.
    13. Anirban Basu & Anupam B. Jena & Dana P. Goldman & Tomas J. Philipson & Robert Dubois, 2014. "Heterogeneity In Action: The Role Of Passive Personalization In Comparative Effectiveness Research," Health Economics, John Wiley & Sons, Ltd., vol. 23(3), pages 359-373, March.
    14. Kristopher J. Hult, 2018. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 185-216, National Bureau of Economic Research, Inc.
    15. Anirban Basu & David Meltzer, 2012. "Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials," PharmacoEconomics, Springer, vol. 30(10), pages 859-868, October.

  3. Meltzer, David O. & Jena, Anupam B., 2010. "The economics of intense exercise," Journal of Health Economics, Elsevier, vol. 29(3), pages 347-352, May.

    Cited by:

    1. Maruyama, Shiko & Yin, Qing, 2012. "The opportunity cost of exercise: Do higher-earning Australians exercise longer, harder, or both?," Health Policy, Elsevier, vol. 106(2), pages 187-194.
    2. Jaume Garcia Villar & María José Suárez, 2021. "The relevance of the specification assumptions when modelling the correlates of physical activity: an analysis across dimensions," Economics Working Papers 1804, Department of Economics and Business, Universitat Pompeu Fabra.
    3. Yong Kang Cheah & Mohd Azahadi & Siew Nooi Phang & Noor Hazilah, 2017. "The Income and Demographic Determinants of Physical Activity Intensity: Evidence from a Developing Country," Margin: The Journal of Applied Economic Research, National Council of Applied Economic Research, vol. 11(3), pages 348-364, August.
    4. Erik Thibaut & John Eakins & Steven Vos & Jeroen Scheerder, 2017. "Time and money expenditure in sports participation: The role of income in consuming the most practiced sports activities in Flanders," Sport Management Review, Taylor & Francis Journals, vol. 20(5), pages 455-467, December.
    5. Lechner, Michael & Sari, Nazmi, 2014. "Labor market effects of sports and exercise: Evidence from Canadian panel data," Economics Working Paper Series 1402, University of St. Gallen, School of Economics and Political Science.
    6. Cabane Charlotte & Lechner Michael, 2015. "Physical Activity of Adults: A Survey of Correlates, Determinants, and Effects," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 235(4-5), pages 376-402, August.
    7. Virpi Kuvaja-Köllner & Hannu Valtonen & Pirjo Komulainen & Maija Hassinen & Rainer Rauramaa, 2013. "The impact of time cost of physical exercise on health outcomes by older adults: the DR’s EXTRA Study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 471-479, June.
    8. Roy, Soumyadip & Orazem, Peter F., 2021. "Active Leisure, Passive Leisure and Health," ISU General Staff Papers 202108200700001838, Iowa State University, Department of Economics.
    9. Nazmi Sari & Michael Lechner, 2015. "Long-Run Health Effects of Sports And Exercise In Canada," Working Papers 150018, Canadian Centre for Health Economics.
    10. García, Jaume & Suárez, María José, 2023. "The relevance of specification assumptions when analyzing the drivers of physical activity practice," Economic Modelling, Elsevier, vol. 119(C).
    11. Michael Lechner & Paul Downward, 2017. "Heterogeneous sports participation and labour market outcomes in England," Applied Economics, Taylor & Francis Journals, vol. 49(4), pages 335-348, January.
    12. Valdez Gonzalez, Natalia I. & Kee, Jennifer Y. & Palma, Marco A. & Pruitt, J. Ross, 2024. "The relationship between monetary incentives, social status, and physical activity," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 108(C).
    13. Finke, Michael S. & Huston, Sandra J., 2013. "Time preference and the importance of saving for retirement," Journal of Economic Behavior & Organization, Elsevier, vol. 89(C), pages 23-34.
    14. Jaana T Kari & Jaakko Pehkonen & Mirja Hirvensalo & Xiaolin Yang & Nina Hutri-Kähönen & Olli T Raitakari & Tuija H Tammelin, 2015. "Income and Physical Activity among Adults: Evidence from Self-Reported and Pedometer-Based Physical Activity Measurements," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-15, August.
    15. Kjær, Trine & Højgaard, Betina & Gyrd-Hansen, Dorte, 2019. "Physical exercise versus shorter life expectancy? An investigation into preferences for physical activity using a stated preference approach," Health Policy, Elsevier, vol. 123(8), pages 790-796.
    16. Jaume Garcia-Villar & María José Suarez, 2021. "The Relevance of the Specification Assumptions when Modelling the Correlates of Physical Activity: an Analysis across Dimensions," Working Papers 1296, Barcelona School of Economics.
    17. Michael Grossman, 2016. "‘A Theory of the Allocation of Time’ Turns Fifty: Its Impact on the Field of Health Economics," Health Economics, John Wiley & Sons, Ltd., vol. 25(1), pages 3-7, January.
    18. Murakami, Keiko & Hashimoto, Hideki & Lee, Jung Su & Kawakubo, Kiyoshi & Mori, Katsumi & Akabayashi, Akira, 2011. "Distinct impact of education and income on habitual exercise: A cross-sectional analysis in a rural city in Japan," Social Science & Medicine, Elsevier, vol. 73(12), pages 1683-1688.
    19. Seung-Yeon Lee & Saemi Jung & Wanhyung Lee, 2022. "Status of Workers’ Health Behavior and the Association between Occupational Characteristics and Health Behavior," IJERPH, MDPI, vol. 19(20), pages 1-13, October.
    20. Jason R. Williams & Yuta J. Masuda & Heather Tallis, 2016. "A Measure Whose Time has Come: Formalizing Time Poverty," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 128(1), pages 265-283, August.
    21. Hyytinen, Ari & Lahtonen, Jukka, 2013. "The effect of physical activity on long-term income," Social Science & Medicine, Elsevier, vol. 96(C), pages 129-137.
    22. Michael Goldsby & James Bishop & Elizabeth Goldsby & Christopher B. Neck & Christopher P. Neck, 2021. "The Impact of Self-Management Practices on Entrepreneurial Psychological States," Administrative Sciences, MDPI, vol. 11(1), pages 1-13, February.
    23. Karen Smith Conway & David P. Niles, 2017. "Cigarette Taxes, Smoking—and Exercise?," Health Economics, John Wiley & Sons, Ltd., vol. 26(8), pages 1019-1036, August.

  4. Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497-518.

    Cited by:

    1. Anirban Basu & Tomas J. Philipson, 2010. "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," NBER Working Papers 15633, National Bureau of Economic Research, Inc.
    2. Jena Anupam B. & Mechoulan Stéphane & Philipson Tomas J., 2013. "Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 83-99, March.
    3. Wilson, Nicholas, 2018. "Altruism in preventive health behavior: At-scale evidence from the HIV/AIDS pandemic," Economics & Human Biology, Elsevier, vol. 30(C), pages 119-129.

  5. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    See citations under working paper version above.
  6. Sun Eric & Jena Anupam B & Lakdawalla Darius & Reyes Carolina & Philipson Tomas J & Goldman Dana, 2010. "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000," Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-22, February.

    Cited by:

    1. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    2. Fatih Safa Erenay & Oguzhan Alagoz & Ritesh Banerjee & Robert R. Cima, 2011. "Estimating the Unknown Parameters of the Natural History of Metachronous Colorectal Cancer Using Discrete-Event Simulation," Medical Decision Making, , vol. 31(4), pages 611-624, July.
    3. Adam Leive & Thomas Stratmann, 2015. "Do national cancer screening guidelines reduce mortality?," Journal of Population Economics, Springer;European Society for Population Economics, vol. 28(4), pages 1075-1095, October.
    4. David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
    5. Seabury Seth A. & Goldman Dana P. & Gupta Charu N. & Khan Zeba M. & Chandra Amitabh & Philipson Tomas J. & Lakdawalla Darius N., 2016. "Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection," Forum for Health Economics & Policy, De Gruyter, vol. 19(1), pages 141-156, June.

  7. Jena Anupam B & Calfee John E. & Mansley Edward C & Philipson Tomas J, 2009. "`Me-Too' Innovation in Pharmaceutical Markets," Forum for Health Economics & Policy, De Gruyter, vol. 12(1), pages 1-21, November.

    Cited by:

    1. McKellar Michael R. & Frank Matthew & Huskamp Haiden & Chernew Michael E., 2012. "The Value of Patent Expiration," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-13, November.
    2. Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
    3. John Rizzo & Richard Zeckhauser, 2009. "Generic script share and the price of brand-name drugs: the role of consumer choice," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 291-316, September.
    4. Siotis, Georges & Ornaghi, Carmine & Castanheira, Micael, 2019. "Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry," CEPR Discussion Papers 14035, C.E.P.R. Discussion Papers.
    5. Michael Mueller & Alexander Frenzel, 2015. "Competitive pricing within pharmaceutical classes: evidence on “follow-on” drugs in Germany 1993–2008," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 73-82, January.
    6. Siotis, Georges & Castanheira, Micael & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2017. "The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma," CEPR Discussion Papers 11813, C.E.P.R. Discussion Papers.
    7. Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.

  8. Jena, Anupam B. & Philipson, Tomas J., 2008. "Cost-effectiveness analysis and innovation," Journal of Health Economics, Elsevier, vol. 27(5), pages 1224-1236, September.

    Cited by:

    1. Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012. "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers 18593, National Bureau of Economic Research, Inc.
    2. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
    3. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    4. Anirban Basu & Tomas J. Philipson, 2010. "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," NBER Working Papers 15633, National Bureau of Economic Research, Inc.
    5. Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson, 2018. "How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations," American Journal of Health Economics, University of Chicago Press, vol. 4(4), pages 433-453, Fall.
    6. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
    7. Jena, Anupam B. & Philipson, Tomas J., 2013. "Endogenous cost-effectiveness analysis and health care technology adoption," Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
    8. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
    9. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    10. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
    11. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
    12. Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010. "Terminal Care and The Value of Life Near Its End," NBER Working Papers 15649, National Bureau of Economic Research, Inc.
    13. Marlon Mundt & Larissa Zakletskaia, 2014. "That’s What Friends Are For: Adolescent Peer Social Status, Health-Related Quality of Life and Healthcare Costs," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 191-201, April.
    14. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015. "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 263-275, July.
    15. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
    16. Afschin Gandjour, 2014. "Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”," PharmacoEconomics, Springer, vol. 32(12), pages 1245-1246, December.
    17. Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
    18. Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497-518.
    19. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
    20. Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2013. "The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 31(5), pages 445-454, May.
    21. Darius Lakdawalla & Anup Malani & Julian Reif, 2015. "The Insurance Value of Medical Innovation," NBER Working Papers 21015, National Bureau of Economic Research, Inc.

  9. Philipson Tomas J & Jena Anupam B, 2006. "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-33, January.
    See citations under working paper version above.

Chapters

  1. Anupam B. Jena & John E. Calfee & Edward C. Mansley & Tomas J. Philipson, 2009. ""Me-Too" Innovation in Pharmaceutical Markets," NBER Chapters, in: Frontiers in Health Policy Research, volume 12, National Bureau of Economic Research, Inc.
    See citations under working paper version above.Sorry, no citations of chapters recorded.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.